Trends of drug licensing in China: From bring-in to go-global

Trends of drug licensing in China: From bring-in to go-global

Blog Article

Global medicine R&D has shown a stabilized trend after fleeting prosperity lately.Despite of discouraging whole picture, the role of China in cross-border out-licensing activities of medical therapeutics keeps rising, which started since 2020 and jacques marie mage baudelaire 2 further boosted in 2023.A holistic analysis of drug and technology licensing, involving Chinese enterprises from 2019 to 2023, revealed 807 license-in deals and 401 license-out deals.In-licensing showed a decreasing trend, while out-licensing was the opposite.Increasing ingenuity of Chinese products has led to a shift from an import-oriented to an export-oriented situation, such as antibody-drug-conjugates, and cell/gene therapies.

With supportive policies of Chinese government, southeast Asia is becoming an important downstream market for out-licensed drugs.Biotech innovators are emerging as a dominant force with core innovation gruvi golden lager capacity.China is embracing international collaboration by showing favorable markets and high-level innovative products.